For instance, the simultaneous application of BRD4 inhibitors and HDAC inhibitors has been shown to limit the growth of tumors and induce programmed cell death (apoptosis) in different tumor models, such as breast cancer, acute myeloid leukaemia, pancreatic ductal adenocarcinoma, neuroblastoma, and cutaneous T-cell lymphoma [135–140]. Here, BRD4 is linked to acute myeloid leukemia.